Antiviral Drugs - Bahrain

Bahrain

The projected revenue in the Antiviral Drugs market in Bahrain is expected to reach US$6.32m in 2024.
It is anticipated that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 1.77%, leading to a market volume of US$6.90m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$30,640.00m in 2024.
Bahrain is experiencing a surge in demand for antiviral drugs due to the country's proactive approach in combating viral outbreaks.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs in Bahrain has been increasing steadily over the past few years.

Customer preferences: Bahrain has a high prevalence of infectious diseases, which has led to an increased demand for antiviral drugs. Additionally, with the recent outbreak of COVID-19, the demand for antiviral drugs has surged.

Trends in the market: The antiviral drugs market in Bahrain is expected to grow at a steady rate due to the increasing prevalence of infectious diseases. The market is also expected to be driven by the rising demand for antiviral drugs to treat COVID-19. Additionally, the increasing availability of generic antiviral drugs is expected to further boost the market growth.

Local special circumstances: Bahrain has a high prevalence of infectious diseases such as hepatitis B and C, which has led to an increased demand for antiviral drugs. The government has implemented various initiatives to control the spread of infectious diseases, which has further increased the demand for antiviral drugs.

Underlying macroeconomic factors: Bahrain has a small population and a high GDP per capita, which has led to a high demand for healthcare services. The government has invested heavily in the healthcare sector, which has led to an increase in the availability of healthcare services, including antiviral drugs. Additionally, the government has implemented various initiatives to control the spread of infectious diseases, which has further increased the demand for antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.